Bruker Corporation recently introduced a groundbreaking technology called EpicIFTM, designed to enhance the CellScape Spatial Proteomics platform. This new technology aims to remove fluorescence signals, expanding antibody compatibility and doubling throughput, all while maintaining tissue integrity and preventing cross-reactivity.
The CellScape platform was initially launched in 2022 and has significantly advanced spatial proteomics with its exceptional quantitative performance, offering high resolution and a wide dynamic range for imaging. By capturing the full spectrum of protein expression in a biological sample and preserving fine morphological details, CellScape has been a game-changer in the field.
With the introduction of EpicIF, the CellScape chemistry has been further improved to allow for a nearly 10-fold increase in compatible commercially available fluorophore-conjugated antibodies. This advancement simplifies assay development and boosts throughput by up to 2-fold. EpicIF achieves this by effectively erasing fluorescence signals from a variety of fluorophores using a proprietary reagent and visible light, all while preserving tissue integrity and epitopes.
To support EpicIF, Bruker has released a new version of the software called CellScape™ Navigator. This software comes with a more user-friendly interface and streamlined experiment setup, making it easier for researchers to utilize the technology. Both EpicIF and CellScape Navigator will be available as upgrades for current CellScape instruments.
According to Ranga Partha, Senior Vice President of Product Management and Marketing at Bruker Spatial Biology, this breakthrough technology offers researchers unparalleled flexibility in highly multiplexed immunofluorescence experiments. By erasing previously photostable fluorophore signals, EpicIF allows for a broader selection of antibody conjugates and compatibility with additional fluorescent readouts, such as RNA-ISH.
Oliver Braubach, Director of R&D Assays at Bruker Spatial Biology, highlighted that EpicIF overcomes the limitations of traditional multiplexing techniques. By erasing signals from a wide range of organic fluorescent dyes without damaging tissues, workflows are simplified, and validated antibodies from other assays can be used, leading to cost and time savings in assay optimization. Additionally, the use of directly-labeled primary antibodies eliminates cross-reactivity commonly observed in other spatial proteomic techniques.
Bruker Spatial Biology will be showcasing this new technology at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. For more information, visit www.brukerspatialbiology.com/EpicIF.
Bruker Spatial Biology, a division of Bruker Corporation, is dedicated to providing advanced spatial solutions for life sciences research, offering instruments, assays, software, and services to support various applications. Their technologies include the CosMx® SMI, GeoMx® DSP, CellScape™ platform, and nCounter® system, among others. Canopy Multiomic Services provide access to these technologies for biopharmaceutical research, custom assay development, and clinical sample testing.
Bruker Corporation, known as a leader in the post-genomic era, focuses on enabling scientists and engineers to make groundbreaking discoveries and develop new applications that enhance human life. Their high-performance scientific instruments and analytical solutions support research in molecular, cellular, and microscopic levels, driving innovation in various fields.
For more information about Bruker Corporation and their innovative technologies, visit www.bruker.com.
